Evidence map›Paper›PMID 32521708›Full record

ArticleGenes2020

Rapid Evaluation of CRISPR Guides and Donors for Engineering Mice.

Elena McBeath, Jan Parker-Thornburg, Yuka Fujii, Neeraj Aryal, Chad Smith, Marie-Claude Hofmann, Jun-Ichi Abe, Keigi Fujiwara

Open access · goldAbstract read
In one paragraph

Article in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Elena McBeathDepartment of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jan Parker-ThornburgDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yuka FujiiDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston TX 77030, USA.
Neeraj AryalDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Chad SmithDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Marie-Claude HofmannDepartment of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jun-Ichi AbeDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston TX 77030, USA.
Keigi FujiwaraDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston TX 77030, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Pathological flow-induced endothelial damage and plaque erosionR01HL149303 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABE, JUN-ICHI, COOKE, JOHN P · 2019 to 2022
$3.2M
A Novel Role for MAGI1 in regulating non-canonical LATS signaling and atherosclerotic plaque formationR01HL134740 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LE, NHAT-TU · 2017 to 2021
$2.0M
Molecular Regulation of the Perinatal Male Germ Cell NicheR01HD081244 · NICHD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HOFMANN, MARIE-CLAUDE CATHERINE · 2014 to 2018
$1.6M
Instituting innovative CRISPR/Cas9 technology at an NCI Comprehensive Cancer Center transgenic facilityR50CA211121 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PARKER-THORNBURG, JAN · 2017 to 2021
$1.2M
Role of BHC80 in spermatogenesisR03HD101650 · NICHD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HOFMANN, MARIE-CLAUDE CATHERINE · 2020 to 2021
$162k
NCI NIH HHS P30 CA016672NCI NIH HHS P30CA016672NCI NIH HHS R50 CA211121NICHD NIH HHS R01 HD081244NICHD NIH HHS R03 HD101650NIH HHS R01HD081244NIH HHS R01HL13019NIH HHS R01HL134740NIH HHS R01HL149303
6 · The paper itself

Abstract

Although the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/ CRISPR associated protein 9 (Cas9) technique has dramatically lowered the cost and increased the speed of generating genetically engineered mice, success depends on using guide RNAs and donor DNAs which direct efficient knock-out (KO) or knock-in (KI). By Sanger sequencing DNA from blastocysts previously injected with the same CRISPR components intended to produce the engineered mice, one can test the effectiveness of different guide RNAs and donor DNAs. We describe in detail here a simple, rapid (three days), inexpensive protocol, for amplifying DNA from blastocysts to determine the results of CRISPR point mutation KIs. Using it, we show that (1) the rate of KI seen in blastocysts is similar to that seen in mice for a given guide RNA/donor DNA pair, (2) a donor complementary to the variable portion of a guide integrated in a more all-or-none fashion, (3) donor DNAs can be used simultaneously to integrate two different mutations into the same locus, and (4) by placing silent mutations about every 6 to 10 bp between the Cas9 cut site and the desired mutation(s), the desired mutation(s) can be incorporated into genomic DNA over 30 bp away from the cut at the same high efficiency as close to the cut.

Indexed as

Genetic EngineeringAnimalsAnimals, Genetically ModifiedBlastocystCRISPR-Cas SystemsMaleMiceMice, KnockoutMutationRNA, Guide, CRISPR-Cas SystemsRNA, Guide, CRISPR-Cas SystemsblastocystCRISPR/Cas9gene targetinggenetic engineeringsilent mutation

Identifiers

PMID32521708
PMCPMC7349695
OpenAlexW3033467537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.